6.17
1.59%
-0.10
After Hours:
6.17
Ocular Therapeutix Inc stock is currently priced at $6.17, with a 24-hour trading volume of 1.18M.
It has seen a -1.59% decreased in the last 24 hours and a -18.60% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $6.22 pivot point. If it approaches the $5.98 support level, significant changes may occur.
Previous Close:
$6.27
Open:
$6.25
24h Volume:
1.18M
Market Cap:
$955.66M
Revenue:
$58.44M
Net Income/Loss:
$-80.74M
P/E Ratio:
-5.1417
EPS:
-1.2
Net Cash Flow:
$-76.32M
1W Performance:
+9.01%
1M Performance:
-18.60%
6M Performance:
+170.61%
1Y Performance:
-3.29%
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
15 Crosby Drive, Bedford, MA
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-21-23 | Initiated | Robert W. Baird | Outperform |
Aug-10-22 | Resumed | Berenberg | Buy |
Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
Dec-17-20 | Initiated | Berenberg | Buy |
Nov-13-20 | Reiterated | Raymond James | Strong Buy |
Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
May-21-19 | Reiterated | H.C. Wainwright | Buy |
May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
Nov-15-18 | Initiated | Raymond James | Strong Buy |
Sep-07-18 | Initiated | Piper Jaffray | Overweight |
Oct-24-17 | Initiated | Guggenheim | Buy |
Jul-26-17 | Initiated | H.C. Wainwright | Buy |
Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
Ocular Therapeutix: 2Q Earnings Snapshot - Yahoo News UK
Yahoo News UK
When the Price of (OCUL) Talks, People Listen - Stock Traders Daily
Stock Traders Daily
Read This Before Selling Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares - Yahoo New Zealand News
Yahoo New Zealand News
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Canada Shine On
Yahoo Canada Shine On
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Loss-Making Ocular Therapeutix, Inc. (NASDAQ:OCUL) Expected To Breakeven - Yahoo New Zealand News
Yahoo New Zealand News
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Ocular Therapeutix Inc (OCUL) Revenue 2024
OCUL reported a revenue (TTM) of $58.44 million for the quarter ending December 31, 2023, a +13.50% rise year-over-year.
Ocular Therapeutix Inc (OCUL) Net Income 2024
OCUL net income (TTM) was -$80.74 million for the quarter ending December 31, 2023, a -13.65% decrease year-over-year.
Ocular Therapeutix Inc (OCUL) Cash Flow 2024
OCUL recorded a free cash flow (TTM) of -$76.32 million for the quarter ending December 31, 2023, a -20.54% decrease year-over-year.
Ocular Therapeutix Inc (OCUL) Earnings per Share 2024
OCUL earnings per share (TTM) was -$1.25 for the quarter ending December 31, 2023, a -22.55% decline year-over-year.
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. The company is also developing OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; and OTX-TKI, a tyrosine kinase inhibitor intravitreal injection that delivers a hydrogel-based anti-angiogenic formulation for the treatment of wet age-related macular degeneration. In addition, it markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. Further, the company engages in the preclinical development of formulations of its hydrogel administered via intravitreal injection to address the diseases and conditions of the back of the eye. Ocular Therapeutix, Inc. has collaboration agreement with Regeneron Pharmaceuticals, Inc. for the development and commercialization of products using its hydrogel in combination with large molecule VEGF-targeting compounds for the treatment of retinal diseases. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Cap:
|
Volume (24h):